Skip to main content
메뉴
로그인
검색
보도자료 배포 서비스 · 뉴스와이어
언론인
고객센터
로그인
회원가입
보도자료 등록
보도자료
서비스
교육
블로그
검색
메뉴
최신
기술
산업
문화
생활
건강
경제
금융
운송
레저
교육
사회
환경
정부
상장기업
영문
기술
가전
게임
과학
네트워킹
데이터 분석
드론
로봇
메타버스
모바일 기기
모바일 앱
반도체
보안
블록체인
소프트웨어
양자와 나노기술
인공지능
기술
인터넷
전자부품
주변기기
컴퓨터
통신
관련 토픽
5세대 이동통신
NFT
가상현실
바이오테크
사물 인터넷
생성형 AI
스마트폰
스마트홈
스타트업
클라우드 서비스
산업
건설과 건축
금속
기계
농업
방위산업
부동산
석유 가스
수산 해양
신재생에너지
임업
전기설비
전력
제조설비
제지 포장
조선
직물
산업
항공우주
화학
관련 토픽
공급망
배터리
수소 에너지
스마트 팩토리
원자력
태양광
문화
공연 예술
디자인
문화유산
미술
방송
소셜 미디어
스트리밍 미디어
신문 잡지
애니메이션
연예인
영화
음악
종교
출판
학술
관련 토픽
무용
문학
뮤지컬
박물관
연극
오페라
웹툰
인플루언서
콘서트
한류
생활
가구
결혼
미용
반려동물
보석류
생활용품
소매
슈퍼마켓
식품 음료
온라인 쇼핑
음식점
의류와 잡화
장난감
주류
출산 육아
화장품
관련 토픽
간편식
명상
봄 시즌
뷰티
쇼핑
신제품 출시
요리
유기농
중고 거래
채식
프로모션
건강
감염 관리
건강기능식품
생명공학
의료 기술
의료기기
의료와 병원
의학
임상시험
정신건강
제약
종양
치과
관련 토픽
면역
바이오테크
식품의약품안전처(FDA)
유전자
줄기세포
중독
코로나바이러스
경제
경제 동향
광고와 마케팅
기업 경영
노동
무역과 박람회
아웃소싱
인재와 고용
중소기업
창업
컨설팅
프랜차이즈
환경 사회 지배구조
회계 세무
관련 토픽
마케팅
소상공인
스타트업
일자리
합작
금융
보험
암호화폐
은행과 금융
자산관리
증권
카드
펀드
핀테크
관련 토픽
결제 서비스
나스닥
배당
비트코인
코스닥
코스피
크라우드 펀딩
투자 유치
운송
교통
물류
철도
항공사
해운
자동차
자율주행
관련 토픽
모빌리티
모터쇼
스마트카
전기차
카셰어링
레저
관광명소
스포츠
야외 레저
여행
축제
호텔 숙박
관련 토픽
골프
등산
카지노
캠핑
크루즈
파리올림픽
해외여행
힐링
교육
교육 일반
대학교
온라인 교육
유아교육
중등교육
직업교육
초등교육
학원
관련 토픽
대학입시
영어 교육
졸업·입학
진로교육
청소년
학교
사회
공공 안전
노인
법률
사회복지
여성
외국인
자선사업
장애인
관련 토픽
1인가구
MZ세대
로펌
비대면
사회적 기업
재택근무
환경
기후변화와 탈탄소
재활용
친환경 기술
환경 보전
환경 정책
관련 토픽
미세먼지
스마트그리드
에너지 절약
폐기물
정부
공공기관
비영리조직
외교
정당
중앙정부
지방정부
관련 토픽
국회
대사관
대통령
선거
지방자치
상장기업
국내 상장기업
해외 상장기업
최신
기술
산업
문화
생활
건강
경제
금융
운송
레저
교육
사회
환경
정부
상장기업
영문
검색
MY
메뉴
보도자료
최신
기술
산업
문화
생활
건강
경제
금융
운송
레저
교육
사회
환경
정부
상장기업
English
보도자료
MY뉴스
사진
동영상
기업 뉴스룸
박람회
토픽
RSS 피드
서울
인천 경기
대전 충남
광주 전남
부산 울산 경남
대구 경북
강원
충북
전북
제주
해외
보도자료
계약
공모
사업 확장
사회공헌
설립
수상
신상품
실적
연구개발
인사
인수 매각
인증
전시
제휴
조사분석
채용
투자
판촉
행사
서비스
왜 뉴스와이어인가
어떻게 배포하나
보도자료 배포 요금
누가 이용하나
스타트업 홍보 지원
회원 혜택
언론 서비스
MY뉴스 소개
보도자료 전송
보도자료 호스팅
교육
교육 개요
홍보 마케팅 전략보고서
언론홍보 핸드북
보도자료 만들기
보도자료 유형
홍보 직무
온라인 강의
자주하는 질문
블로그
홍보의 모든 것
고객센터
회사 소개
사이트맵
Boehringer Ingelheim International GmbH
구독하기
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
구독하기
RSS
337개
2015년 6월 1일
10:00
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib* and erlotinib, in patients with advanced squamous ...
건강
제약
연구개발
2015년 5월 29일
09:30
Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and E...
건강
제약
연구개발
2015년 5월 28일
10:45
Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio June 5-9 at the American Diabetes Association’s® (ADA) 75th Scientific Sessions in Boston. Th...
건강
제약
행사
2015년 5월 27일
09:25
FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved as a long-term, once-daily maintenance treatmen...
건강
제약
연구개발
2015년 5월 21일
11:55
New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy[1,2,3]
Boehringer Ingelheim today announced new data analyses from the pivotal Phase III TONADO® 1&2 studies[4] (NCT01431274, / NCT01431287, ). Data showed tiotropium/olodaterol Respimat®‡ provided lung function benefit to patients with chronic obstructi...
건강
제약
연구개발
2015년 5월 18일
18:20
Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH an...
건강
제약
연구개발
2015년 5월 18일
18:15
New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups
Boehringer Ingelheim announced new data and analyses for OFEV® (nintedanib*) reinforcing its efficacy, safety and tolerability in a broad range of patients with idiopathic pulmonary fibrosis (IPF). These findings were presented at the American Tho...
건강
제약
연구개발
2015년 5월 14일
15:45
Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO 2015 with new data including presentation of afatinib* overall survival results for squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 29 May - 2 June 2015. A total of 9 abstracts, includ...
건강
제약
연구개발
2015년 5월 14일
11:40
First patient enrolled in dabigatran study comparing anticoagulation strategies during AF ablation
The first patient with atrial fibrillation (AF) has been enrolled in the global RE-CIRCUIT™ study.[4] The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa®) during ablation procedures compa...
건강
제약
연구개발
2015년 4월 20일
10:15
New international survey of lung cancer oncologists highlights underutilization of personalized treatments
For media outside the US, the UK and Canada only Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for EGFR mutations, a sig...
건강
제약
연구개발
2015년 4월 14일
10:35
Hydra Biosciences and Boehringer Ingelheim Enter Research Collaboration Focused on Renal Diseases and Disorders
Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer Ingelheim today announced that they have entered into a worldwide research collaboration and license agreement to identify smal...
건강
제약
제휴
2015년 3월 30일
16:15
Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union
For media outside the US, the UK and Canada only Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) today announced they have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medic...
건강
제약
연구개발
2015년 3월 17일
10:20
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces two analyses from the GLORIA™-AF Registry Program examining the use of anticoagulant treatments for stroke prevention in patients with atrial fibrillation (AF).[1,2] These n...
건강
제약
연구개발
2015년 3월 4일
10:15
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canad...
건강
제약
연구개발
2015년 1월 27일
17:30
New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
For media outside the US, the UK and Canada Boehringer Ingelheim today announced that the first patient has been enrolled into its large-scale DYNAGITO® study.[1] It will assess the potential benefit of tiotropium + olodaterol Respimat® FDC† compa...
건강
제약
연구개발
2015년 1월 19일
17:45
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will...
건강
제약
연구개발
2015년 1월 15일
10:45
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in Cancer Research and Profess...
건강
제약
제휴
2015년 1월 14일
11:25
Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas
Boehringer Ingelheim announced today collaboration with Yale University, New Haven, Connecticut, USA, with the goal of researching novel therapeutic targets in the field of immune-modulation. Immune-modulation refers to a range of treatments aimed...
건강
제약
제휴
2015년 1월 12일
16:40
The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy
Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6) in epidermal growth factor receptor (EGFR) mutation-positive patien...
건강
제약
연구개발
2014년 12월 16일
09:55
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source
For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embol...
건강
제약
연구개발
2014년 12월 9일
17:50
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
For Non-US/Non-UK/Non-Canadian Media New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexi...
건강
제약
연구개발
2014년 11월 27일
17:50
Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
For media outside UK, US and Canada only Today Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU. Vargatef® in combination with ...
건강
제약
연구개발
2014년 11월 24일
16:10
Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF
For media outside UK, US and Canada Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib* (suggested brand name OFEV...
건강
제약
연구개발
2014년 11월 19일
18:45
New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans
For Non-US/Non-UK/Non-Canadian Media New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism. In...
건강
제약
연구개발
2014년 11월 19일
18:40
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
For Non-US/Non-UK/Non-Canadian Media Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with ...
건강
제약
연구개발
2014년 11월 7일
19:50
New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy
For Media In Asian Countries Only For Whom The Data Is Relevant (For media outside UK, US and Canada only) Boehringer Ingelheim today announced data from a pre-specified subgroup-analysis of the pivotal Phase III LUX-Lung 3 trial which demonstrate...
건강
제약
연구개발
2014년 11월 4일
10:35
FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice
Non US, Non UK, Non Canadian Media On October 30, 2014, the U.S. Food and Drug Administration (FDA) Medicare analysis of 134,000 atrial fibrillation (AF) patients treated with either Pradaxa® (dabigatran etexilate) or warfarin in a general practic...
건강
제약
연구개발
2014년 10월 22일
11:40
Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments
For Ex-US and Ex-UK Media Only Boehringer Ingelheim today announced the enrolment of the first patient in a new global Phase III study in patients with advanced colorectal cancer (CRC). Colorectal cancer is the third most common cancer in the worl...
건강
제약
연구개발
2014년 10월 17일
17:45
Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis
For media outside UK, US and Canada Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved OFEV™ (nintedanib*) for the treatment of idiopathic pulmonary fibrosis (IPF), a debilitating and fatal lung diseas...
건강
제약
연구개발
2014년 9월 29일
16:30
Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
For Ex-US and Ex-UK Media Only Phase III data from Boehringer Ingelheim’s LUX-Lung 8 trial, the first study to directly compare the efficacy of two different targeted agents in patients with advanced squamous cell carcinoma (SCC) of the lung, demo...
건강
제약
연구개발
2014년 9월 29일
16:15
Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung
For media outside UK and US only Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of nintedanib* (suggested br...
건강
제약
연구개발
2014년 9월 22일
10:15
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
For Ex-US and Ex-UK Media Only Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on...
건강
제약
제휴
2014년 9월 17일
15:20
Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
Boehringer Ingelheim and Eli Lilly and Company today presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) alr...
건강
제약
연구개발
2014년 9월 10일
18:25
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting
Data to be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehring...
건강
제약
연구개발
2014년 9월 10일
18:10
Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline
For media outside UK, US and Canada A pre-specified subgroup analysis from the two replicate Phase III INPULSIS™ trials, presented today at the European Respiratory Society International Congress (ERS), showed nintedanib* slowed disease progressio...
건강
제약
연구개발
2014년 9월 10일
17:25
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD
For media outside the US, the UK and Canada Data from the pivotal phase III TONADO™ studies†,1 for tiotropium + olodaterol Respimat® FDC were presented for the first time today at the European Respiratory Society (ERS) International Congress 2014....
건강
제약
연구개발
2014년 9월 10일
17:15
Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
For media outside the US, the UK & Canada only Boehringer Ingelheim today announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU. Spiriva® Respimat® is indicated as an...
건강
제약
연구개발
2014년 9월 3일
10:35
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin
Non-US/Non-UK/Non-Canadian Media New data presented today indicate that kidney function decline is less pronounced in patients with an irregular heartbeat (non-valvular atrial fibrillation, NVAF) who are treated with Pradaxa® (dabigatran etexilate...
건강
제약
연구개발
2014년 9월 2일
09:10
Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention
For Non-US/Non-UK/Non-Canadian Media Five years on from the first breakthrough presentation of the pivotal RE-LY® clinical trial of Pradaxa® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF),[4] extensi...
건강
제약
연구개발
2014년 9월 1일
17:05
Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014
For media outside UK, US and Canada The European Respiratory Society (ERS) International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfoli...
건강
제약
연구개발
2014년 8월 25일
17:35
New Pradaxa® data to be presented at the ESC Congress 2014
For Non-US/Non-UK/Non-Canadian Media New Pradaxa® (dabigatran etexilate) data for the treatment of a broad range of thromboembolic diseases will be presented at the ESC Congress 2014, 30th August - 3rd September, 2014, Barcelona, Spain, organised ...
건강
제약
연구개발
2014년 8월 19일
17:45
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
INGELHEIM, Germany--(BUSINESS WIRE)-- For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCITM.[1] The study will evaluat...
건강
제약
연구개발
2014년 7월 18일
10:30
Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA Breakthrough Therapy designation in IPF
For non-U.S. Media Only Boehringer Ingelheim today announced that for the first time the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis (IPF), a devastating and f...
건강
제약
연구개발
2014년 7월 9일
11:45
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
For media outside of the US/UK only Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer.1,2 It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World.1 The current ...
건강
제약
연구개발
2014년 7월 2일
17:20
COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD
For media outside the US, the UK and Canada Boehringer Ingelheim today announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft...
건강
제약
연구개발
2014년 7월 1일
11:45
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote
For media outside of the U.S., the UK & Canada only The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab* (a humanized antibody fragment), currently being studied as ...
건강
제약
연구개발
2014년 6월 20일
17:30
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of un...
건강
제약
연구개발
2014년 6월 17일
13:15
Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
For Non-U.S. and Non-U.K. Media Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with...
건강
제약
연구개발
2014년 6월 16일
16:35
New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia
For media outside of the US/UK only Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old.[1] For older patients who receive chemotherapy, the median survival is less than a year.[2] Even ...
건강
제약
조사분석
2014년 6월 16일
01:05
Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition
Non-US and Non-UK The first insights from IntroDia™ presented at the American Diabetes Association's (ADA) 74th Scientific Sessions®, showed that over three quarters (76-100 percent across 26 countries) of 6,753 physicians surveyed agree that conv...
건강
제약
연구개발
4
5
6
7
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기
닫기
로그인
검색
섹션
계정